期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非小细胞肺癌的化学治疗现状及进展 被引量：3

下载PDF
导出
摘要 随着越来越多循证医学的支持及有效的化疗新药的出现,化疗在NSCLC的多学科综合治疗中正占据越来越重要的地位。本文对目前常用化疗药物、化疗方案及化疗在各期NSCLC中的地位做一综述。
作者 李洪霞 蔡少华
机构地区 解放军总医院南楼呼吸科
出处 《中国药物应用与监测》 CAS 2007年第2期4-7,共4页 Chinese Journal of Drug Application and Monitoring
关键词 非小细胞肺癌 4E疗药物
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1吴一龙,Giorgio Scagliotti,陈治宇.培美曲塞(Alimta~)治疗非小细胞肺癌新进展[J].中国癌症杂志,2006,16(8):605-608. 被引量：11
  • 2[4]Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non small cell lung cancer previously treated with chemotherapy[J].J Clin Oncol,2004,22(9):1589.
  • 3[6]Arriagada R,Bergman B,Dunant A,et al.The International Adjuvant Lung Cancer Trial Collaborative Group:Cisplatin-based adjuvant chemotherapy in patients with completely resected nonsmall-cell lung cancer[J].N Engl J Med,2004,350(4):351.
  • 4[7]Strauss GM,Herndon J,Maddaus MA,et al.Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC):Report of cancer and leukemia group B (CALGB) protocol 9633[J].Proc Am Soc of Clin Oncol,2004:Abstract 7019.
  • 5[8]Winton T,Livingston R,Johnson D,et al.Vinorelbine plus cisplatin vs.observation in resected non-small-cell lung cancer[J].N Engl J Med,2005,352(25):2589.
  • 6[9]Douillard J Y,Rosell R,Delena M,et al.ANITA:Phase Ⅲ adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage Ⅰ-Ⅲ) non-small-cell lung cancer (NSCLC) patients (pts):Final results after 70-month median follow-up.On behalf of the adjuvant navelbine international trialist association[J].J Clin Oncol (Meeting Abstracts),2005,23(Suppl 16S):7013.
  • 7[10]Pisters K,Ginsberg R,Giroux D,et al for the Bimodality Lung Oncology Team.Bimodality lung oncology team (BLOT) trial of induction paclitaxel/carboplatin in early stage nonsmall cell lung cancer (NSCLC):Long term follow-up of a phase Ⅱ trial[J].Proc Am Soc Clin Oncol,2003:633 (abstract 2544).
  • 8[11]Dillman RO,Seagren SL,Propert KJ,et al.A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage Ⅲ non small-cell lung cancer[J].N Engl J Med,1990,323(14):940.
  • 9[12]Le Chevalier T,Arriagada R,Quoix E,et al.Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non small-cell lung cancer:first analysis of a randomized trial in 353 patients[J].J Natl Cancer Inst,1991,83(6):417.
  • 10[13]Dillman RO,Seagren SL,Herndon J,et al.A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage Ⅲ non small-cell lung cancer:Five-year followup of cancer and leukemia group B (CALGB) 8433 trial[J].Proc Am Soc Clin Oncol,1993,12:329.

二级参考文献31

  • 1吴一龙,杨学宁,杨衿记,黄玉娟.中国的非小细胞肺癌Gefitinib分子靶向治疗[J].中国肺癌杂志,2004,7(4):318-320. 被引量：15
  • 2[1]Ryan PD,Chabner BA.On receptor inhibitors and chemotherapy[J].Clin Cancer Res,2000,6 (12):4607.
  • 3[2]Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer[J].J Clin Oncol,2003,21 (21):2237.
  • 4[3]LoRusso PM,Herbst RS,Rischin D,et al.Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non small cell lung cancer and other solid tumors[J].Clin Cancer Res,2003,9 (6):2040.
  • 5[4]Giaccone G,Johnson DH,Manegold C,et al.A phase Ⅲclinical trial of ZD 1839 (Iressa)in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer(INTACT1)[J].Ann Oncol,2002,13:2.
  • 6[5]Johnson M,Herbst R,Giaccone G,et al.ZD1839 (Iressa)in combination with paclitaxel and carboplatin in chemotherapy.naive patients with advanced non-small-cell lung cancer(NSCLC):results from a phase Ⅲ clinical trail (INTACT2)[J].Ann Oncol,2002,13:127.
  • 7[7]Huang SF,Liu HP,Li LH,et al.High frequency of epidermal growth factor receptor mutations with complex patterns in non small cell lung cancers related to gefitinib responsiveness in Taiwan[J].Clin Cancer Res,2004,10(24):8195.
  • 8[8]Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in the epidermal frowth factor receptor underlying responsiveness of non small cell lung cancer to gefitinib[J].N Engl J Med,2004,350(21):2129.
  • 9[9]Tokumo M,Toyooka S,Kiura K,et al.The relationship between epidermal growth factor receptor mutation and clinicopathologic features in non small cell lung cancer[J].Clin Cancer Res,2005,11 (3):1167.
  • 10[10]Inoue A,Saijo Y,Maemondo M,et al.Severe acute interstitial pneumonia and gefitinib[J].Lancet,2003,361 (9352):137.

共引文献12

同被引文献23

引证文献3

二级引证文献11

中国药物应用与监测
2007年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部